Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination product containing two active ingredients: - **Lactobacillus paracasei GM-080** (also known as Lacticaseibacillus paracasei GM-080), a probiotic strain shown to modulate immune responses, reduce airway inflammation, and alleviate symptoms of allergic diseases such as allergic rhinitis. It acts by stimulating interferon-gamma (IFN-γ) and interleukin-12 (IL-12) production, enhancing Th1 immune responses, and reducing IgE-mediated inflammation. The strain is considered safe, non-toxic, and able to survive gastrointestinal transit[1][2][5]. - **Fluticasone propionate**, a synthetic glucocorticoid corticosteroid widely used as an anti-inflammatory agent in the treatment of allergic rhinitis and asthma. It works by binding to the glucocorticoid receptor to suppress pro-inflammatory gene expression. The combination aims to provide both immunomodulatory effects from the probiotic component and potent anti-inflammatory action from the corticosteroid for enhanced management of airway inflammatory conditions such as allergic rhinitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lactobacillus paracasei GM-080 + fluticasone propionate.